Literature DB >> 25515131

Severe resistant maternal hypotension following tocolysis with nifedipine.

Freda Khoo1, Manisha Mathur1.   

Abstract

An 18-year-old woman, gravida 3, para 2, presented at 24 weeks of gestation with preterm premature rupture of membranes. She was started on nifedipine for tocolysis and to facilitate administration of steroids. Two and a half hours later, the patient developed tachycardia and hypotension. Sepsis from chorioamnionitis, acute cardiac event and pulmonary embolism were considered as differential diagnoses. Laboratory and radiological investigations, however, ruled out these possible causes of haemodynamic instability. Her clinical condition deteriorated and hypotension remained intractable despite aggressive fluid resuscitation. An emergency caesarean section at 24 weeks of gestation was carried out in the interest of saving the mother's life. The haemodynamic status of the patient recovered rapidly postcaesarean section. This case report highlights the rare but potentially serious adverse effects of hypotension in administration of nifedipine; and thus reminds us of the importance of judicious prescription and careful titration of nifedipine as a tocolytic. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25515131      PMCID: PMC4275729          DOI: 10.1136/bcr-2014-208059

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Severe hypotension and fetal death due to tocolysis with nifedipine.

Authors:  A J van Veen; M J Pelinck; M G van Pampus; J J H M Erwich
Journal:  BJOG       Date:  2005-04       Impact factor: 6.531

2.  A randomized comparison of nifedipine and ritodrine for suppression of preterm labor.

Authors:  C A Koks; H A Brölmann; M J de Kleine; P A Manger
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1998-04       Impact factor: 2.435

3.  Gestational changes in uterine L-type calcium channel function and expression in guinea pig.

Authors:  P L Collins; J J Moore; D W Lundgren; E Choobineh; S M Chang; A S Chang
Journal:  Biol Reprod       Date:  2000-11       Impact factor: 4.285

4.  Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial.

Authors:  D N Papatsonis; H P Van Geijn; H J Adèr; F M Lange; O P Bleker; G A Dekker
Journal:  Obstet Gynecol       Date:  1997-08       Impact factor: 7.661

5.  Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis.

Authors:  V Tsatsaris; D Papatsonis; F Goffinet; G Dekker; B Carbonne
Journal:  Obstet Gynecol       Date:  2001-05       Impact factor: 7.661

6.  A comparison of three tocolytics for preterm labor: a randomized clinical trial.

Authors:  Chad K Klauser; Christian M Briery; Rick W Martin; LeDon Langston; Everett F Magann; John C Morrison
Journal:  J Matern Fetal Neonatal Med       Date:  2013-10-11

Review 7.  Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomised trials.

Authors:  Aravinthan Coomarasamy; Ellen M Knox; Harry Gee; Fujian Song; Khalid S Khan
Journal:  BJOG       Date:  2003-12       Impact factor: 6.531

8.  Side-effect and vital sign profile of nifedipine as a tocolytic for preterm labour.

Authors:  L W Chan; D S Sahota; S Y Yeung; T Y Leung; T Y Fung; T K Lau; T N Leung
Journal:  Hong Kong Med J       Date:  2008-08       Impact factor: 2.227

9.  Calcium channel blockers as tocolytics: principles of their actions, adverse effects and therapeutic combinations.

Authors:  Róbert Gáspár; Judit Hajagos-Tóth
Journal:  Pharmaceuticals (Basel)       Date:  2013-05-23
  9 in total
  1 in total

1.  Randomized Controlled Trials of Tianma Gouteng Decoction Combined with Nifedipine in the Treatment of Primary Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Jia Tai; Junbo Zou; Xiaofei Zhang; Yu Wang; Yulin Liang; Dongyan Guo; Mei Wang; Chunli Cui; Jing Wang; Jiangxue Cheng; Yajun Shi
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-07       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.